Patents by Inventor Guo-Liang Yu

Guo-Liang Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220049005
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: April 7, 2021
    Publication date: February 17, 2022
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Publication number: 20220049006
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: April 15, 2021
    Publication date: February 17, 2022
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Patent number: 11001637
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 11, 2021
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10796787
    Abstract: Provided are methods for identifying T-cell receptors that bind to an antigen in primates. In certain embodiments, the methods comprise: sequencing the cDNA prepared from a combined population of T-cells to obtain a plurality of T-cell receptor alpha chain sequences and a plurality of T-cell receptor beta chain sequences; grouping the obtained alpha chain sequences into alpha chain groups based on their CDR3 sequences; grouping the obtained beta chain sequences into beta chain groups based on their CDR3 sequences; pairing the alpha chain groups with the beta chain groups based on the number of alpha chain or beta chain sequences in each group; pairing one alpha chain sequence and one beta chain sequence in each paired alpha chain group and beta chain group; and testing candidate T-cell receptor comprising the paired alpha chain and beta chain sequences for binding to the antigen.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: October 6, 2020
    Inventor: Guo-liang Yu
  • Publication number: 20200283831
    Abstract: The present disclosure provides a method for detecting multiple target nucleic acid sequences in a sample using a plurality of IDed double-stranded probes. Each IDed double-stranded probe comprises a double-stranded nucleic acid hybridization probe associated with an IDed substrate. Also provided is a method for determining the sequence of a nucleic acid by using a plurality of IDed double-stranded probes.
    Type: Application
    Filed: March 18, 2020
    Publication date: September 10, 2020
    Inventors: Xiaojun LEI, Yuan YUAN, Guo-liang YU, Qiang LI
  • Patent number: 10613094
    Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: April 7, 2020
    Assignee: EPITOMICS, INC.
    Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace, Guo-Liang Yu
  • Publication number: 20190309080
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: February 27, 2019
    Publication date: October 10, 2019
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20180320223
    Abstract: The present disclosure provides a method for detecting multiple target nucleic acid sequences in a sample using a plurality of IDed double-stranded probes. Each IDed double-stranded probe comprises a double-stranded nucleic acid hybridization probe associated with an IDed substrate. Also provided is a method for determining the sequence of a nucleic acid by using a plurality of IDed double-stranded probes.
    Type: Application
    Filed: March 20, 2016
    Publication date: November 8, 2018
    Inventors: Xiaojun LEI, Yuan YUAN, Guo-liang YU, Qiang LI
  • Publication number: 20180322244
    Abstract: Provided are methods for identifying T-cell receptors that bind to an antigen in primates. In certain embodiments, the methods comprise: sequencing the cDNA prepared from a combined population of T-cells to obtain a plurality of T-cell receptor alpha chain sequences and a plurality of T-cell receptor beta chain sequences; grouping the obtained alpha chain sequences into alpha chain groups based on their CDR3 sequences; grouping the obtained beta chain sequences into beta chain groups based on their CDR3 sequences; pairing the alpha chain groups with the beta chain groups based on the number of alpha chain or beta chain sequences in each group; pairing one alpha chain sequence and one beta chain sequence in each paired alpha chain group and beta chain group; and testing candidate T-cell receptor comprising the paired alpha chain and beta chain sequences for binding to the antigen.
    Type: Application
    Filed: June 28, 2018
    Publication date: November 8, 2018
    Inventor: Guo-liang Yu
  • Publication number: 20180273630
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 27, 2018
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10042975
    Abstract: Provided are methods for identifying antibodies that bind to an antigen in primates. In certain embodiments, the methods comprise: sequencing the cDNA prepared from a combined population of antibody-producing B-cells to obtain a plurality of antibody heavy chain sequences and a plurality of antibody light chain sequences; grouping the obtained antibody heavy chain sequences into heavy chain groups based on their CDR3 sequences; grouping the obtained antibody light chain sequences into light chain groups based on their CDR3 sequences; pairing the heavy chain groups with the light chain groups based on the number of antibody heavy chain or light chain sequences in each group; pairing one antibody heavy chain sequence and one light chain sequence in each paired heavy chain group and light chain group; and testing candidate antibodies comprising the paired heavy chain and light chain sequences for binding to the antigen.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 7, 2018
    Assignee: Qyuns Therapeutics Co., Ltd.
    Inventor: Guo-liang Yu
  • Patent number: 9994640
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 12, 2018
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20170246297
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20170233483
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Patent number: 9725728
    Abstract: The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: August 8, 2017
    Assignee: Mendel Biotechnology, Inc.
    Inventors: Bradley K. Sherman, Jose Luis Riechmann, Cai-Zhong Jiang, Jacqueline E. Heard, Volker Haake, Robert A. Creelman, Oliver J. Ratcliffe, Luc J. Adam, T. Lynne Reuber, James S. Keddie, Pierre E. Broun, Marsha L. Pilgrim, Arnold N. DuBell, III, Omaira Pineda, Guo-Liang Yu
  • Patent number: 9696314
    Abstract: In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: July 4, 2017
    Assignee: EPITOMICS, INC.
    Inventor: Guo-Liang Yu
  • Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20170146551
    Abstract: The present disclosure relates methods for identifying antibodies that binds to an antigen in primates.
    Type: Application
    Filed: July 13, 2016
    Publication date: May 25, 2017
    Inventor: Guo-liang Yu
  • Patent number: 9556278
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 31, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu